Tag: technology

Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Fitness App Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)" report has been added to ResearchAndMarkets.com's offering.

The global fitness app market is undergoing a remarkable transformation, fueled by growing health consciousness, technological innovation, and a shift in consumer preferences towards virtual fitness solutions. According to recent industry analysis, the market is projected to reach a valuation of US$ 11.78 billion in 2025 and soar to US$ 31.2 billion by 2032, expanding at a robust CAGR of 14.92% during the forecast period. This dynamic growth trajectory underscores the market's resilience and its adaptability to emerging digital trends.

Market Insights

Fitness applications have become an integral part of modern wellness lifestyles, enabling users to access personalized workout routines, track progress, and engage with health professionals remotely. The increasing use of smartphones, wearable devices, and smartwatches has further expanded the user base for fitness apps.

The evolution of fitness apps from simple step counters to comprehensive health monitoring platforms reflects a broader transformation in the wellness sector. With the integration of artificial intelligence and machine learning, apps now offer real-time recommendations and adaptive workout plans, enhancing user engagement and experience.

Key Market Drivers

PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company’s Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.